Maravai Lifesciences Holdings, Inc. (MRVI): Total Assets
$770.58M
As of 2025-12-31
$603.75M
As of 2026-06-30
-30.4%
3-year compound annual growth
-9.5%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $770.58M | -23.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $1.01B | n/a | 2026-02-26, Balance as of period end |
| 2024-09-30 | $1.28B | n/a | 2025-03-18, Balance as of period end |
| 2024-06-30 | $1.44B | n/a | 2025-03-18, Balance as of period end |
| 2023-12-31 | $1.49B | -34.8% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $2.28B | +19.0% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $1.92B | +51.0% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $1.27B | n/a | 2022-03-01, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $770.58M | -23.6% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $418.43M | +54.1% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $62.11M | -13.7% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $764.99M | +8.7% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $259.15M | -31.5% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $529.71M | -26.9% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $670.77M | -2.1% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $488.95M | -25.5% |
Compare MRVI, STOK, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗